Company Overview of SR One
SR One is the venture capital arm of GlaxoSmithKline specializing in investing in seed, start up, early and mid venture; and emerging growth companies. It seeks to invest in emerging life science companies that are pursuing innovative science which will significantly impact medical care, with products in preclinical development stage through clinical proof-of-concept; biotechnology; healthcare; medical devices, and related information technologies companies. It typically invests in companies based globally with a focus on the United States, Canada, and Europe. The firm typically invests between $500,000 and $5 million per round. It prefers to take a board seat or observers right in its portf...
161 Washington Street
Eight Tower Bridge
Conshohocken, PA 19428-2077
Founded in 1985
Key Executives for SR One
Compensation as of Fiscal Year 2014.
SR One Key Developments
SR One Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 09:00 AM
Sep 10 14
SR One Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 09:00 AM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Brian M. Gallagher, Partner.
SR One Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014
Jul 31 14
SR One Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland. Presentation Date & Speakers: Sep-30-2014, David Phillips, Partner, Deborah Harland, Partner.
SR One Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-17-2014 12:30 PM
Jun 17 14
SR One Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-17-2014 12:30 PM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada. Speakers: Vikas Goyal, Senior Associate.
Similar Private Companies By Industry
Recent Private Companies Transactions